Current Reports (8-K / 6-K)

Divested 100% equity of Particle, Inc. for $1 cash plus 10% revenue share on covered products for up to 5 years.

Buyer assumes all business obligations including Seattle office lease.

Issued secured promissory note up to $450,000 at 10% interest maturing September 23, 2026.

Ronald P. Erickson departed as Board member and Science Division President effective March 27, 2026.

Transaction approved by independent Audit Committee; not material to financial statements.

Strategic shift to focus on core fintech tokenized deposit offering.

The company acquired assets and licenses for Honeywell's general aviation autopilot, nav/com, display, and transponder product lines for $22.0 million in cash.

The company acquired assets and licenses for Honeywell's electronic generator and generator control unit for the F-15 and 767 platforms for $8.0 million in cash.

Both transactions closed concurrently with the signing of the agreements, representing completed acquisitions.

The agreements include customary representations, warranties, covenants, and mutual indemnification obligations.

Transition Services Agreements were also executed, under which Honeywell will provide technical support to assist the company in manufacturing, repairing, and servicing the licensed products.

Submitted CardiAMP HF clinical study data to the FDA — first formal regulatory submission for the CardiAMP® System in ischemic HFrEF.

Requested FDA meeting this quarter under Breakthrough Therapy designation — timing aligns with prior regulatory guidance and signals advancement toward potential accelerated approval.

Meeting objectives include FDA feedback on acceptability of approval based on safety, clinical response in 125 ischemic HFrEF patients, and benefit in elevated biomarker subgroup.

In the elevated biomarker subgroup, CardiAMP showed 47% relative risk reduction in all-cause cardiac death and 37% reduction in non-fatal major adverse cardiac events versus guideline-directed medical therapy alone.

Results presented at THT 2026 Annual Meeting and posted on BioCardia’s website — public validation of clinical data by a peer-reviewed forum.

Company exchanged Prior Notes for Exchange Note with original principal of $2,681,718.42 including OID of $242,883.49 and $10,000 transaction expenses.

Interest rate reduced from 18% per annum on Prior Notes to 6% per annum compounded daily on Exchange Note.

Maturity extended from March 31, 2026 to July 1, 2027.

Streeterville can require monthly redemptions up to $111,738.27 starting July 1, 2026.

Obligations guaranteed by subsidiary Virtuix Inc.

Exchange qualifies under Section 3(a)(9) of Securities Act with tacked holding period from Prior Notes' issuance dates.

Dr. Howard Berman resigned as Executive Chairman and Director effective April 1, 2026, following a planned CEO transition process initiated in November 2024.

Mark H. Pavao was appointed as an independent Class III Director to fill the vacancy, with a term expiring at the 2028 annual meeting.

The Company entered into a Separation Agreement with Dr. Berman providing for a prorated 2026 bonus and 12 months of continued stock option vesting.

Mr. Pavao brings over 30 years of biopharmaceutical leadership experience and will receive an option to purchase 10,000 shares of common stock.

Parties: Itaú Unibanco Holding S.A. and Itaú Unibanco S.A. with Porto Seguro S.A., Porto Seguro Seguros Del Uruguay S/A, and Azul Companhia de Seguros Gerais.

Transaction: Operating Agreement for promotion and sale of Porto Seguro insurance via Itaú Unibanco channels.

Remuneration exceeded BRL 50 million monthly per CVM Resolution 80/22 threshold.

Management confirms compliance with commutative conditions and related party policy.

Recurring in normal course of business; no further disclosures for 2026.

Estimated total 2026 remuneration: approximately BRL 441 million.

Agreement dated April 1, 2026, between Company and Purchaser(s) listed in Exhibit A.

Issuing up to 20,000 Class B ordinary shares, par value $0.000012 each.

Purchase price of $3.20 per share.

Purchaser is a non-US person under Regulation S, for own account.

Closing at offices of Hunter Taubman Fischer & Li LLC upon conditions met.

Pre-agreement capitalization: 944,784 Class A and 3,846 Class B ordinary shares outstanding.

FDA accepted for review the resubmitted Biologics License Application for UX111 gene therapy for Sanfilippo syndrome Type A.

The FDA set a Prescription Drug User Fee Act action date of September 19, 2026.

The company is seeking accelerated approval for UX111.

The press release contains forward-looking statements about the development, regulatory review, and potential approval of UX111.

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially.

Holders of the company's units can elect to separate them into Class A ordinary shares and warrants starting April 6, 2026.

Separated Class A ordinary shares will trade under the symbol 'WLII' and warrants under 'WLIIW' on the Nasdaq Global Market.

Units that are not separated will continue to trade under the symbol 'WLIIU' on the Nasdaq Global Market.

Each whole warrant entitles the holder to purchase one Class A ordinary share for $11.50.

Holders must have their brokers contact Continental Stock Transfer & Trust Company to separate units into shares and warrants.

Selig Zises resigned effective March 31, 2026, citing personal health and related disability.

The resignation was not due to any disagreement with the Company, the Bank, or their affiliates.

Mr. Zises served for more than 17 years on the Board.

The Board of Directors was reduced from nine to eight directors following the resignation.

Entered master services agreement with Iterative Health (d/b/a Iterative Health) on March 30, 2026, to assist with patient enrollment for the expected Phase 2 study of PALI-2108 in moderate-to-severe UC — accelerates clinical execution readiness.

Issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health on March 27, 2026, for $3.0 million total consideration — provides non-dilutive capital aligned with clinical development partner.

Pricing of $1.952 per share was set at the five-day Nasdaq Capital Market average closing price prior to March 27, 2026 — establishes objective, market-based valuation for the private placement.

Offering exempt from registration under Section 4(a)(2) of the Securities Act — confirms reliance on private placement exemption without public registration or prospectus.

Received signed purchase order from Latin American public safety organization for drone-based operational systems and integrated payloads.

Order includes long-range quadrotor platforms, EO/IR imaging, network connectivity, and specialized aerial payloads for defense and surveillance missions.

Phased deployment structure with initial tranche in 2026, subject to delivery milestones, quantity confirmations, and standard commercial terms.

Follows technical presentations to government officials referenced in March 16, 2026 press release.

No assurance of full completion or revenue realization due to customary conditions including performance and acceptance.

Potential foundation for broader engagements in the jurisdiction and region if initial deployment succeeds.

All seven directors re-elected with majority support, Samarth Verma receiving lowest For votes at 2,543,827.

Merger with New Asia Holdings Inc. and Preferred Stock conversion failed with 3,839,210 For vs 306,347 Against.

RBSM LLP ratified as independent auditor for 2025 with 5,293,058 For votes.

Nasdaq-compliant share issuances to Generating Alpha Ltd. and JAK Industrial Ventures I LLC approved.

Authorized Common Stock increased from 75M to 3B shares; reverse stock split (1:10-1:20) approved.

Stock Incentive Plan expanded by 1.5M shares plus annual 4.5% evergreen increase approved.

Acquired all membership interests of RPD Technologies Americas from controlling shareholder Abundia Financial for $4.04 million, payable via a convertible note.

Issued a $4.04 million senior secured convertible note to Abundia Financial with 10% annual interest, maturing on the first anniversary of closing.

The convertible note can be converted into common stock after maturity at 80% of the average VWAP over three trading days, subject to a $0.29 per share floor price.

Granted a security interest in the acquired membership interests to Abundia Financial as collateral for the convertible note obligation.

The acquisition adds an immediate revenue stream and expands Abundia's vertically integrated waste-to-value business model with RPD's project development capabilities.

The securities issued were not registered under the Securities Act, relying on exemptions for transactions not involving a public offering.

FDA granted Fast Track designation to CDI-988, the first oral antiviral for norovirus treatment and prophylaxis.

Designation enables frequent FDA communication, rolling NDA review, and potential Priority Review.

Phase 1b challenge study underway at Emory University evaluating CDI-988 in up to 40 healthy adults.

CDI-988 targets conserved region of norovirus, coronavirus, and other 3CL proteases.

Norovirus causes 685 million global cases yearly with $60 billion economic impact.

Tender offer expired April 1, 2026, with $110,390,000 Notes tendered after Early Tender Date.

Total Notes accepted for purchase: $893,995,000, below $1,000,000,000 maximum.

Includes $783,605,000 previously accepted on March 19, 2026.

Settlement for late tenders on April 3, 2026.

Notes originally issued by Civitas, assumed by SM Energy post-merger.

No minimum tender condition; offer managed by BofA Securities and D.F. King.

Annual Meeting scheduled for May 6, 2026 at 12:00 p.m. Toronto time, conducted virtually via live audio webcast — enables broader shareholder participation but restricts physical attendance.

Meeting agenda includes receipt of audited consolidated financial statements for fiscal year ended December 31, 2025 — no financial results or performance commentary disclosed in this filing.

Directors to be elected for the ensuing year; nominees explicitly named: Ronald Dewhurst, Graham Birch, Barbara Connolly Keady, Dinaz Dadyburjor, Whitney George, Judith W. O’Connell, and Catherine Raw — no changes to board composition disclosed.

KPMG LLP to be re-appointed as auditor with Board authorized to fix remuneration — no auditor change or qualification disclosed.

Notice-and-access delivery used per NI 51-102 and NI 54-101 — reduces paper use and mailing costs; meeting materials posted online at sedarplus.ca and sprott.com/investor-relations/2026-agm.

Record date is March 17, 2026; proxy deadline is May 4, 2026 at 12:00 p.m. Toronto time — late proxies subject to Chair’s discretion.

Seth Kalvert will leave his position as Chief Legal Officer and Secretary effective May 1, 2026.

The departure is treated as a Qualifying Termination under the Amended and Restated Executive Severance Plan.

Mr. Kalvert's departure involves no disagreement with the Company regarding operations, policies, or practices.

Mr. Kalvert has agreed to remain available in an advisory capacity to assist with transition services.

US District Court for the Southern District of New York largely denied defendants' joint motion to dismiss the lawsuit.

Lawsuit alleges spoofing techniques manipulated Quantum BioPharma share price between January 1, 2020, and August 15, 2024.

Claims violate Section 10(b), Rule 10b-5(a) and (c), and Section 9(a) of the Securities Exchange Act of 1934.

Court's full ruling available as District Court Opinion & Order.

Claim referenced as USD $700,000,000 in exhibit title.

Q1 2026 production totaled 10,236 vehicles at the Normal, Illinois manufacturing facility.

Q1 2026 deliveries totaled 10,365 vehicles, exceeding production for the quarter.

Management stated quarterly results are in line with the company's outlook.

The company reaffirmed 2026 annual delivery guidance in the range of 62,000 to 67,000 vehicles.

Q1 2026 financial results are scheduled for release on April 30, 2026, after market close.

Entered Merger Agreement on April 2, 2026, to acquire The Container Store Holdings, LLC through Merger Sub merger.

Merger consideration: $150M Purchase Price via Buyer Common Stock at $7.00/share and senior convertible notes with $54M minimum, subject to 19.99% ownership cap.

Buyer Convertible Notes: 5% interest, 7-year maturity, initial conversion at ~$9.10/share, interest escalates without stockholder approval.

Appointed Brian LaRose as CFO effective April 28, 2026, succeeding Adrianne B. Lee; Amy E. Sullivan as President and Lisa Foley as COO tied to TBHC merger.

Support Agreement signed by holders of 80.47% TCS equity and 90.75% term loans.

Closing subject to lender approvals, $55M new loans, financial statements, no later than September 30, 2026.

Off The Hook YS Inc. entered a definitive agreement to acquire Bellhart Marine Group and its affiliated entities.

The acquisition aims to build a premier marine 'Mega Service & Refit Center' platform in the Carolinas.

The transaction includes three strategic facilities: Cape Fear River Shipyard, Market Street Facility, and Sloop Point Marina.

The acquisition is expected to accelerate inventory reconditioning timelines and improve gross margins.

The transaction is subject to customary closing conditions including due diligence and third-party approvals.

Company added cancer cachexia—a serious, untreatable cancer-associated wasting syndrome affecting up to 80% of advanced cancer patients—as a new core indication.

No FDA-approved therapies currently exist for cancer cachexia in the U.S., representing a major unmet medical need and commercial opportunity.

Global cancer cachexia market projected to grow from $2.54 billion in 2024 to $3.90 billion by 2033, per Grand View Research cited in the filing.

Lead candidate Phyto-N remains in preclinical studies for ulcerative colitis, with a planned IND submission; cancer cachexia expansion is concurrent and complementary.

Strategic pivot aligns with Curanex’s broader focus on serious diseases involving inflammation, metabolic dysfunction, and physical decline.

Q1 2026 tender requests reached 21.9% of shares outstanding as of Dec 31, 2025, with 5% ($988M) fulfilled pro rata, driven by small minority of investors.

Gross inflows of $872M resulted in net outflows of $116M, less than 1% of Dec 31, 2025 NAV.

Liquidity of $11.3B as of Feb 28, 2026 provides 11x coverage of tender; net leverage 0.80x below 0.90x-1.25x target.

Portfolio at $36B fair value as of Dec 31, 2025: 370 companies, 93% senior secured, 91% PE-backed, 0.3% non-accruals.

OCIC Class I annualized return 9.2% since inception through Feb 28, 2026, outperforming public credit indices.

Moody’s upgraded rating from Baa3 to Baa2 in Jan 2026 citing underwriting and track record.

OTIC received estimated tender requests of 40.7% of shares outstanding but will fulfill only 5% on a pro rata basis.

The 5% tender fulfillment totals $179 million, partially offset by $127 million in gross capital inflows.

Liquidity stands at over $1.3 billion as of February 28, 2026, providing approximately 7x coverage of the tender offer.

Net leverage was 0.82x debt-to-equity, below the target range of 0.90x to 1.25x.

Non-accruals remained low at 0.2% of portfolio fair value with a 0.0% average annual net loss rate since inception.

Acquired SE&M entities for $158 million in cash, subject to closing adjustments; potential earnout up to 8% of purchase price based on post-acquisition performance targets.

SE&M generated $109 million revenue and high-teens EBITDA margin in 2025, with ~65% of revenue from mechanical services and ~60% from pharmaceutical and health care end markets.

Transaction enhances Everus’ Southeast presence, diversifies revenue mix, and adds recurring maintenance and retrofit revenue with high client renewal rates.

SE&M leadership—including CEOs Zack and Alex Bynum and President Patrick Rogers—will remain post-acquisition, ensuring continuity and operational execution.

Pro forma net leverage is expected to be 0.8x, preserving financial flexibility for organic growth and additional strategic acquisitions.

Reverse stock split ratio set at 1-for-7.7, effective March 31, 2026 at 5:00 P.M. Eastern Time.

Outstanding common stock decreased from approximately 3.9 million pre-split shares to approximately 500,000 post-split shares.

Authorized common stock shares remain unchanged at 100 million shares.

Trading on Nasdaq began on a split-adjusted basis on April 1, 2026, with new CUSIP 05072K404.

Fractional shares rounded up to whole shares at the participant level with DTC; no fractional shares issued.

Outstanding warrants, options, and convertible securities will be proportionately adjusted.

Reverse stock split ratio set at 1-for-7.7, effective March 31, 2026 at 5:00 P.M. Eastern Time.

Outstanding common stock decreased from approximately 3.9 million pre-split shares to approximately 500,000 post-split shares.

Authorized common stock shares remain unchanged at 100 million shares.

Trading on Nasdaq began on a split-adjusted basis on April 1, 2026, with new CUSIP 05072K404.

Fractional shares rounded up to whole shares at the participant level with DTC; no fractional shares issued.

Outstanding warrants, options, and convertible securities will be proportionately adjusted.

Peter Anastasiou appointed COO effective April 2, 2026, with $600,000 base salary and 55% target bonus — strengthens operational leadership amid growth phase.

Anastasiou resigned from Board effective April 2, 2026, with no disagreement cited — eliminates dual role and aligns governance with executive responsibilities.

Troy Ignelzi appointed Class III director effective April 2, 2026, and to Audit and Compensation Committees effective May 14, 2026 — adds CFO-level finance and governance expertise.

Antonio Gracias, Class III director since 2017 and current Compensation Committee chair, will not stand for re-election at the May 14, 2026 Annual Meeting — marks planned board refreshment.

Anastasiou’s employment agreement includes $3.7M stock option award vesting 25% annually over four years and severance equal to one year’s base salary upon termination without cause — establishes clear retention and transition terms.

The company sold its Vonore, Tennessee property for $16,000,000, expecting net proceeds of approximately $14.6 million after costs.

Proceeds were used to prepay a portion of the company's existing term loan facility, reducing its leverage profile.

The company entered a 20-year lease for the property with an initial annual base rent of approximately $1.4 million, increasing 3.5% annually.

The transaction is expected to provide additional cash flow for deleveraging while maintaining operational continuity at the facility.

Management stated the transaction builds on recent momentum and positions the company for future growth and shareholder value.

Received NYSE American letter on March 31, 2026, confirming regained compliance with Section 1003(a)(ii) stockholders' equity requirement.

Previously, on August 19, 2025, NYSE American accepted Company's compliance plan.

Met $4.0 million stockholders' equity threshold after two consecutive compliant quarters per Section 1009(f).

Compliance indicator removed from ROLR trading symbol starting April 1, 2026.

Company now subject only to NYSE American's normal continued listing monitoring.

Issued press release on April 2, 2026, announcing the compliance regain.

Company entered into an underwriting agreement for a public offering of 10,345,000 shares of common stock at $29.00 per share.

Expected net proceeds to the Company are approximately $282 million after underwriting discounts and expenses.

Underwriters have a 30-day option to purchase up to an additional 1,551,750 shares.

Offering is expected to close on or about April 6, 2026, subject to customary closing conditions.

Intended use of proceeds includes funding commercial readiness for barzolvolimab, clinical development, platform growth, and general corporate purposes.

Launched generic methadone hydrochloride 5 mg and 10 mg tablets under Elite Laboratories, Inc. label.

Product indicated for severe pain management and opioid addiction detoxification/maintenance treatment.

2025 annual retail sales for brand and generic methadone tablets were approximately $22 million per IQVIA data.

Press release furnished as Exhibit 99.1, not deemed filed under Section 18 of the Exchange Act.

Priced CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes in offshore transactions under Regulation S.

Notes consist of CNY7.5 billion 2.05% notes maturing in 2031 and CNY2.5 billion 2.75% notes maturing in 2036.

Proceeds will be used for general corporate purposes, including repayment of certain existing indebtedness and payment of interest.

Notes are not registered under the U.S. Securities Act and may not be offered or sold in the United States or to U.S. persons.

Expected listing on The Stock Exchange of Hong Kong Limited; closing subject to customary conditions.

Priced CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes in offshore transactions under Regulation S.

Notes consist of CNY7.5 billion 2.05% notes maturing in 2031 and CNY2.5 billion 2.75% notes maturing in 2036.

Proceeds will be used for general corporate purposes, including repayment of certain existing indebtedness and payment of interest.

Notes are not registered under the U.S. Securities Act and may not be offered or sold in the United States or to U.S. persons.

Expected listing on The Stock Exchange of Hong Kong Limited; closing subject to customary conditions.

Attributable gold production of 765,900 ounces for 2025 met the mid-point of guidance, driven by record quarterly output at all operations.

Full-year revenues were $2,852.8 million from sales of 817,800 ounces at an average realized gold price of $3,482 per ounce.

Net earnings attributable to equity holders were $664.4 million for 2025, with adjusted net earnings of $709.2 million.

The company expects 2026 attributable production in the range of 720,000 to 820,000 ounces.

Proven and Probable Mineral Reserves (100% basis) total 9.9 million ounces of gold as of December 31, 2025.

Available liquidity was $868.6 million as of December 31, 2025, with net debt reduced by $514.9 million during the year.

Amended and restated ABL Credit Facility of up to $2,400 million replaces prior $2,600 million facility — reflects reduced committed capacity and refinancing on updated terms.

$130 million First In, Last Out (FILO) tranche retained — preserves incremental senior secured lending layer with distinct priority and pricing.

Interest rates tied to Term SOFR or Base Rate plus spreads ranging from 0.125% to 1.375%, dependent on Daily Average Availability — introduces tiered cost structure linked to liquidity usage.

Maturity set for April 1, 2031, but may accelerate to 91 days before maturity of either the $500 million term loan (if >$100M outstanding) or 6.750% senior notes due 2028 (if >$100M outstanding) — introduces structural maturity linkage to other debt.

Fixed charge coverage ratio covenant of 1.0:1.0 triggered if adjusted aggregate availability falls below greater of $204 million or 10% of Borrowing Base — adds earnings-based compliance requirement not present in prior facility.

Borrowing Base includes 90% of eligible receivables and 90.0–92.5% of net orderly liquidation value of eligible inventory — collateral valuation methodology explicitly disclosed and unchanged from prior practice.

Engaged Geophysical Studies Chile to conduct an IP survey targeting sulphides up to 500 m deep across two grids totaling 37 line km — direct step toward drill target refinement.

Carrizal hosts >12 km of mapped, sampled veining with surface samples including 17.25% Cu and 8.4 g/t Au — confirms high-grade potential but management cautions on selectivity of rock samples.

Drilling has tested only 1.5 km of the >12 km veining to ~200 m depth — IP survey aims to extend understanding of mineralization continuity and depth extent.

Next steps include structural interpretation, 3D IP inversion, LiDAR-assisted modeling, and integration with surface sampling to enhance drill targeting confidence.

Executive Vice President Robert F. Buesinger will transition to Special Advisor to the President effective April 2, 2026.

Brian Powers was appointed as Senior Vice President, Performance & Essential Materials Segment Head effective April 2, 2026.

The changes are connected to Mr. Buesinger's upcoming retirement.

The Board of Directors approved both the transition and appointment on March 30, 2026.

The leadership change affects the Performance & Essential Materials segment management.

Sold ~$5M worth of common stock (par value $0.001/share) on April 1, 2026.

Sale price based on NAV per share as of March 31, 2026; NAV and share count to be disclosed within 20 business days.

Shares to be credited to investor accounts as of April 1, 2026; Form 8-K amendment to follow.

No underwriting discounts or commissions paid.

Exempt from Securities Act registration under Section 4(a)(2) and Rule 506(b) of Regulation D.

No general solicitation or public offering conducted.

The First Amendment to the Merger Agreement revises the definition of 'Fully-Diluted Company Shares' and introduces new terms for 'In-the-Money Vested Company Options' and 'In-the-Money Unvested Company Options'.

Certain holders of Teamshares preferred stock may elect to receive a liquidation preference at closing, forfeiting their right to future earnout shares.

The amendment increases the shares reserved for the post-closing Incentive Plan from 5% to 7% of outstanding common stock and adds an annual evergreen increase.

A new employee stock purchase plan (ESPP) will be submitted for shareholder approval, reserving shares equal to 2% of post-closing outstanding common stock.

Execution of employment agreements by each member of the Management Team is now a condition to closing for Live Oak.

A separate Second Letter Agreement Amendment releases up to 1,150,000 Incentive Founder Shares from transfer restrictions at closing if used to secure financing or non-redemption commitments.

The First Amendment to the Merger Agreement revises the definition of 'Fully-Diluted Company Shares' and introduces new terms for 'In-the-Money Vested Company Options' and 'In-the-Money Unvested Company Options'.

Certain holders of Teamshares preferred stock may elect to receive a liquidation preference at closing, forfeiting their right to future earnout shares.

The amendment increases the shares reserved for the post-closing Incentive Plan from 5% to 7% of outstanding common stock and adds an annual evergreen increase.

A new employee stock purchase plan (ESPP) will be submitted for shareholder approval, reserving shares equal to 2% of post-closing outstanding common stock.

Execution of employment agreements by each member of the Management Team is now a condition to closing for Live Oak.

A separate Second Letter Agreement Amendment releases up to 1,150,000 Incentive Founder Shares from transfer restrictions at closing if used to secure financing or non-redemption commitments.

The First Amendment to the Merger Agreement revises the definition of 'Fully-Diluted Company Shares' and introduces new terms for 'In-the-Money Vested Company Options' and 'In-the-Money Unvested Company Options'.

Certain holders of Teamshares preferred stock may elect to receive a liquidation preference at closing, forfeiting their right to future earnout shares.

The amendment increases the shares reserved for the post-closing Incentive Plan from 5% to 7% of outstanding common stock and adds an annual evergreen increase.

A new employee stock purchase plan (ESPP) will be submitted for shareholder approval, reserving shares equal to 2% of post-closing outstanding common stock.

Execution of employment agreements by each member of the Management Team is now a condition to closing for Live Oak.

A separate Second Letter Agreement Amendment releases up to 1,150,000 Incentive Founder Shares from transfer restrictions at closing if used to secure financing or non-redemption commitments.

Units (PAACU) can be separated into ordinary shares (PAAC) and warrants (PAACW) starting April 6, 2026.

Each unit consists of one ordinary share and one-half of one redeemable warrant.

Whole warrants entitle holders to purchase one ordinary share for $11.50 per share.

Holders must contact Continental Stock Transfer & Trust Company through their brokers to separate units.

The company is a blank check company that has not selected a business combination target.

The company will consolidate its Class A ordinary shares at a 1-for-3 ratio, reducing issued shares from 4,686,248 to approximately 1,562,083.

The consolidation is intended to increase the per share trading price to meet Nasdaq's minimum bid price requirement for continued listing.

Post-consolidation trading under the symbol 'CHR' will begin on April 7, 2026, with a new CUSIP number G39973139.

No fractional shares will be issued; any fractional shares resulting from the consolidation will be rounded up to the next whole number.

Outstanding warrants and other equity rights will be proportionately adjusted to reflect the share consolidation.

The Annual General Meeting is scheduled for May 5, 2026, at 2:30 p.m. ET in a virtual-only format.

2025 attributable gold production reached approximately 765,900 ounces, a 15% year-over-year improvement.

Two directors, Dr. Ann Masse and Ms. Audra Walsh, are not standing for re-election at the upcoming AGM.

Daniel Racine is standing for election to the Board, bringing over 35 years of global mining leadership experience.

Shareholders will vote on amendments to the Share Incentive Plan and an advisory resolution on executive compensation.

H25D-6083 intersected 53.4m at 304.14 g/t Ag and 1.33 g/t Au (4.86 g/t AuEq), including 0.9m at 2,890 g/t Ag and 33.70 g/t Au (67.26 g/t AuEq).

New structural intersection identified at Vortex, expanding targets at depth and along strike.

Q1 2026 ended with $189M unrestricted cash, debt free.

Q1 pre-tax expenses of $33.8M from compensation actions, using $19.4M cash.

Expanding exploration with two additional core rigs at Vortex and Brimstone.

Updated corporate presentation posted on website April 2, 2026.

Veea converted $16.9 million in promissory notes held by affiliate NLabs Inc. into 168,764 shares of Series A Preferred Stock.

The company also converted $4.3 million in unpaid rent obligations to NLabs and 83 rd Street LLC into 43,236 shares of the same Preferred Stock.

In connection with the note conversion, Veea issued a warrant to NLabs to purchase 33,551,486 shares of common stock at $0.503 per share.

The company is transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market to gain additional time to meet minimum bid price and market value requirements.

The conversions were intended to ensure the company's stockholders' equity would be at least $5 million, aiding compliance with Nasdaq Capital Market listing rules.

Veea converted $16.9 million in promissory notes held by affiliate NLabs Inc. into 168,764 shares of Series A Preferred Stock.

The company also converted $4.3 million in unpaid rent obligations to NLabs and 83 rd Street LLC into 43,236 shares of the same Preferred Stock.

In connection with the note conversion, Veea issued a warrant to NLabs to purchase 33,551,486 shares of common stock at $0.503 per share.

The company is transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market to gain additional time to meet minimum bid price and market value requirements.

The conversions were intended to ensure the company's stockholders' equity would be at least $5 million, aiding compliance with Nasdaq Capital Market listing rules.

QIND's fiscal year 2025 revenue grew 45.9% to $16.3 million, with non-GAAP adjusted net income of $564,465 versus a prior year loss.

QIND wrote off approximately $3.5 million in non-recoverable assets and reduced accounts payable by 45% during fiscal year 2025.

For fiscal year 2026, QIND targets approximately $20 million in revenue, driven by expansion of its Al Shola Gas subsidiary.

QIND's gross margin declined to 29.4% in fiscal year 2025 from 35.5% in the prior year.

The company cited risks including potential disruptions from ongoing conflicts in the Persian Gulf region affecting operations.